期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 13, 期 5, 页码 605-621出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728220902866851
关键词
cancer; drug discovery; proteasome; proteasome inhibitor; targeted therapy; ubiquitin
Background: The ubiquitin-proteasome pathway functions as a main pathway in intracellular protein degradation and plays a vital role in almost all cellular events. Various inhibitors of this pathway have been developed for research purposes. The recent approval of bortezomib (PS-341, Velcade (R)), a proteasome inhibitor, for the treatment of multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and other components of the ubiquitin-proteasome pathway. Objectives: We review the current understanding of the ubiquitin-proteasome pathway and inhibitors targeting this pathway, including proteasome inhibitors, as candidate drugs for chemical therapy. Methods: Preclinical and clinical data for inhibitors of the proteasome and the ubiquitin-proteasome pathway are discussed. Conclusions: The proteasome and other members in the ubiquitin-proteasome pathway have emerged as novel therapeutic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据